## KING & SPALDING

King & Spalding LLP 1700 Pennsylvania Avenue, NW Suite 200 Washington, DC 20006-4707 Tel: +1 202 737 0500 Fax: +1 202 626 3737 www.kslaw.com

Thomas J. Spulak Direct Dial: +1 202 661 7948 tspulak@kslaw.com

VIA HAND DELIVERY VIA U.S. MAIL

February 21, 2014

Mr. Jeff S. Jordan Office of the General Counsel Federal Election Commission 999 E Street, NW Washington, DC 20463

**RE: MUR 6748** 

Dear Mr. Jordan;

We are writing to you on behalf of our client, the Pharmaceutical Research and Manufacturers of America ("PhRMA"), in regards to your recent letter informing PhRMA that the complainant in MUR 6748 has provided the Federal Election Commission (the "FEC" or "Commission") with additional information. We appreciate this opportunity to respond. After reviewing the additional information, we note that it is neither relevant nor new.

The additional information regarding Footnote 1 serves merely to complete the legal citation for an article that, *inter alia*, provides readily publicly-available information regarding the lobbying expenditures of PhRMA. Moreover, PhRMA's constitutionally-protected right to engage in lobbying is irrelevant to the allegations contained in the original complaint.

The copy of the email provides no new information from that which was already described fully in the original complaint. It adds nothing to the complaint; any issues raised by the complainant regarding the email were addressed by PhRMA in its response to the Commission dated November 25, 2013.

Mr. Jeff S. Jordan February 21, 2014 Page 2

In conclusion, the additional information does nothing to alter our position that there is no basis to any suggestion or claim that PhRMA violated the Federal Election Campaign Act of 1971, as amended ("FECA"), or its accompanying regulations. Accordingly, we reiterate our request that the Commission find no reason to believe that PhRMA violated FECA or its accompanying regulations.

Sincerely,

Thomas J. Spulak